Study Description
Brief Summary
The purpose of the study will be to demonstrate whether Mohs micrographic surgery can be
performed with a lower total dose of local anesthesia (and greater patient safety) when using
0.5% lidocaine with 1:200,000 epinephrine versus 1% lidocaine with 1:100,000 epinephrine.
Detailed Description
The purpose of the study will be to demonstrate whether Mohs micrographic surgery can be
performed with a lower total dose of local anesthesia (and greater patient safety) when using
0.5% lidocaine with 1:200,000 epinephrine versus 1% lidocaine with 1:100,000 epinephrine.
Mohs micrographic surgery is a multi-staged, same-day procedure used to remove skin cancers
under local anesthesia. Reconstruction of the surgical wound is also performed under local
anesthesia, usually immediately after achieving tumor clearance.
This randomized, double-blind study will systematically compare the total dose of 1.0%
lidocaine with 1:100,000 epinephrine versus 0.5% of lidocaine with 1:200,000 epinephrine
needed to achieve local anesthesia during Mohs micrographic surgery (MMS). All healthy adult
volunteers (18 years or older) undergoing Mohs micrographic surgery at the Hospital of the
University of Pennsylvania's Department of Dermatology and Dermatologic Surgery between June
1, 2007 and August 31, 2007 will be eligible to participate in the study. Our primary
intervention will be to record the total dose of lidocaine administered throughout all of the
MMS stages and reconstructions using either of the two lidocaine concentrations. A secondary
intervention will be to record each patient's level of pain control in order to demonstrate
that patient comfort is effectively achieved with a lower total dose of local anesthesia.
Pregnant or breast-feeding subjects, those with a history of allergic or other adverse
reaction to lidocaine or epinephrine, and those who are cognitively impaired will be
excluded. In addition, if the surgeon believes that a patient has a tumor which, due to size
or anatomic site, may put him at risk for requiring a dose of lidocaine that approaches the
threshold of toxicity, this patient will be excluded from the study.
Condition or disease |
Intervention/treatment |
Phase |
|
|
N/A
|
Tracking Information
First Submitted Date | January 02, 2008 |
Last Update Posted Date | January 03, 2008 |
Start Date | June 01, 2007 |
Actual Completion Date | September 01, 2007 |
Primary Completion Date | N/A |
Results First Submitted Date | N/A |
Received Results Disposit Date | N/A |
Current Primary Outcome Measures
-
The primary outcome is a measurement of the total dose of lidocaine (measured in mg) administered to the patient over the course of Mohs micrographic surgery.
[Time Frame: One day]
Original Primary Outcome Measures
Not Available
Current Secondary Outcome Measures
-
The secondary outcome is subject pain, as assessed by a visual analog pain scale and by the volume of extra rescue lidocaine needed during surgery.
[Time Frame: One day]
Original Secondary Outcome Measures
Not Available
Study Design
Brief Title | Comparison of the Total Dose and Efficacy of Two Lidocaine Concentrations Needed for Cutaneous Surgery Local Anesthesia |
Official Title | A Randomized, Double Blind Comparison of the Total Dose of 1.0% Lidocaine With 1:100,000 Epinephrine Versus 0.5% Lidocaine With 1:200,000 Epinephrine Needed to Achieve Effective Anesthesia During Mohs Micrographic Surgery |
Brief Summary |
The purpose of the study will be to demonstrate whether Mohs micrographic surgery can be
performed with a lower total dose of local anesthesia (and greater patient safety) when using
0.5% lidocaine with 1:200,000 epinephrine versus 1% lidocaine with 1:100,000 epinephrine.
|
Detailed Description |
The purpose of the study will be to demonstrate whether Mohs micrographic surgery can be
performed with a lower total dose of local anesthesia (and greater patient safety) when using
0.5% lidocaine with 1:200,000 epinephrine versus 1% lidocaine with 1:100,000 epinephrine.
Mohs micrographic surgery is a multi-staged, same-day procedure used to remove skin cancers
under local anesthesia. Reconstruction of the surgical wound is also performed under local
anesthesia, usually immediately after achieving tumor clearance.
This randomized, double-blind study will systematically compare the total dose of 1.0%
lidocaine with 1:100,000 epinephrine versus 0.5% of lidocaine with 1:200,000 epinephrine
needed to achieve local anesthesia during Mohs micrographic surgery (MMS). All healthy adult
volunteers (18 years or older) undergoing Mohs micrographic surgery at the Hospital of the
University of Pennsylvania's Department of Dermatology and Dermatologic Surgery between June
1, 2007 and August 31, 2007 will be eligible to participate in the study. Our primary
intervention will be to record the total dose of lidocaine administered throughout all of the
MMS stages and reconstructions using either of the two lidocaine concentrations. A secondary
intervention will be to record each patient's level of pain control in order to demonstrate
that patient comfort is effectively achieved with a lower total dose of local anesthesia.
Pregnant or breast-feeding subjects, those with a history of allergic or other adverse
reaction to lidocaine or epinephrine, and those who are cognitively impaired will be
excluded. In addition, if the surgeon believes that a patient has a tumor which, due to size
or anatomic site, may put him at risk for requiring a dose of lidocaine that approaches the
threshold of toxicity, this patient will be excluded from the study.
|
Study Type | Interventional |
Study Phase | N/A |
Estimated Enrollment | 149 |
Allocation | Randomized |
Interventional Model | Parallel Assignment |
Masking | Quadruple |
Primary Purpose | Not Available |
Conditions |
Anesthesia
|
Target Follow-Up Duration | N/A |
Biospecimen: |
N/A
|
Sampling Method | N/A |
Study Population | N/A |
Intervention |
Drug:
lidocaine
Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
|
Study Groups/Cohorts |
0.5% lidocaine group
Group that receives 0.5% lidocaine with 1:200,000 epinephrine
1.0% lidocaine group
Group that receives 1.0% lidocaine with 1:100,000 epinephrine
|
Study Arms |
Experimental
0.5% lidocaine group
Group that receives 0.5% lidocaine with 1:200,000 epinephrine
Drug :
lidocaine
Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
Experimental
1.0% lidocaine group
Group that receives 1.0% lidocaine with 1:100,000 epinephrine
Drug :
lidocaine
Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
|
Arm |
Intervention/Treatment |
Experimental
0.5% lidocaine group
Group that receives 0.5% lidocaine with 1:200,000 epinephrine
|
Drug :
lidocaine
Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
|
Experimental
1.0% lidocaine group
Group that receives 1.0% lidocaine with 1:100,000 epinephrine
|
Drug :
lidocaine
Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
|
Recruitment Information
Recruitment Status: | Completed |
Enrollment | 149 |
Completion Date | September 01, 2007 |
Eligibility Criteria: |
Inclusion Criteria: - 18 years or older - Mohs micrographic surgery patient Exclusion Criteria: - Pregnant or breast-feeding subjectsH - History of allergic or other adverse reaction to lidocaine or epinephrine - Cognitively impairment - Surgeon judges patient a risk for lidocaine toxicity due to tumor size
|
Gender | All |
Age | 18 Years to N/A |
Accepts Healthy Volunteers | No |
Contacts |
Not Available
|
Listed Location Countries |
Not Available
|
Administrative Information
NCT Number: | NCT00594542 |
Other Study ID Numbers |
UPenn IRB-806101
|
Has Data Monitoring Committee | Yes |
U.S. FDA-regulated Product |
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Device Product Not Approved or Cleared by U.S. FDA: No
|
IPD Sharing Statement |
Not Available
|
Responsible Party | Christopher J. Miller, M.D., |
Study Sponsor |
|
Collaborators |
Not Available
|
Investigators |
Principal Investigator
Christopher J Miller, MD
University of Pennsylvania Department of Dermatology
|